Advanced Filters
noise

friedreichs-ataxia Clinical Trials

A listing of friedreichs-ataxia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 16 clinical trials
K Krisin L Wade, M.Litt.

NAD+ and Exercise in FA

Randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on VO2max and Si in Friedreich's Ataxia (FA). The primary objective of this research is to measure the effect of combination administration (NR + exercise) on aerobic capacity (VO2max) in FA. A …

10 - 40 years of age Both Phase N/A
M Michaela Kolarova

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver …

18 - 50 years of age Both Phase 1/2
M Madeline Galbraith, BS

Phase IA Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, …

18 - 50 years of age Both Phase 1

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

To assess the safety and tolerability of single and multiple doses of MTR-601 in normal healthy volunteers under fed and fasted conditions. To evaluate the plasma and urine pharmacokinetics (PK) of MTR-601. To evaluate the pharmacodynamic (PD) effects of MTR-601 on muscle strength and muscle accumulation of MTR-601 by muscle …

18 - 45 years of age Both Phase 1
C Claudia P Eisenlohr, MIB

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

6 - 100 years of age Both Phase 4
M MacKenzi Coker

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.

- 100 years of age Both Phase N/A
F Francisco Javier Rodriguez de Rivera

Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)

This is a multi-centre, multi-national, prospective, observational study of Friedreich's Ataxia (FRDA) with a control group to: obtain natural history data on individuals affected by FRDA relate clinical assessments and results from proteomic analyses expedite identification and recruitment of participants for clinical trials develop and validate sensitive and reliable outcome …

- 100 years of age Both Phase N/A
M MacKenzi Coker

FA Clinical Outcome Measures

This multicenter natural history study aims to expand the network of clinical research centers in FA, and to provide a framework for facilitating therapeutic interventions. In addition, this study will lead to the development of valid yet sensitive clinical measures crucial to outcome assessment of patients with Friedreich's Ataxia. This …

4 - 80 years of age Both Phase N/A
C CoRDS Team

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures …

- 100 years of age Both Phase N/A
L Laurent Servais, MD, PhD

Baby Detect : Genomic Newborn Screening

Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the early start of transformative treatment will help avoid severe disabilities and increase the quality of …

- 28 years of age Both Phase N/A

Rewrite in simple language using AI